Maxim Group Upgrades Reviva Pharmaceuticals (NASDAQ:RVPH) to Buy

Reviva Pharmaceuticals (NASDAQ:RVPH - Get Free Report) was upgraded by equities research analysts at Maxim Group from a "hold" rating to a "buy" rating in a report released on Friday,Benzinga reports. The brokerage presently has a $7.00 price objective on the stock. Maxim Group's price target would indicate a potential upside of 272.34% from the stock's current price.

Several other brokerages have also weighed in on RVPH. EF Hutton Acquisition Co. I raised Reviva Pharmaceuticals to a "strong-buy" rating in a report on Monday, September 23rd. Roth Mkm began coverage on shares of Reviva Pharmaceuticals in a research report on Friday. They issued a "buy" rating and a $7.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $11.25.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ RVPH traded up $0.01 during mid-day trading on Friday, reaching $1.88. 4,427,622 shares of the company's stock were exchanged, compared to its average volume of 3,583,298. The firm has a 50-day moving average price of $1.54 and a two-hundred day moving average price of $1.28. The firm has a market capitalization of $62.87 million, a price-to-earnings ratio of -1.69 and a beta of -0.12. Reviva Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $4.83.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) by 17.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 278,496 shares of the company's stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 63.18% of the company's stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.